Advertisement

Basic Principles of Molecular Pathophysiology and Etiology of Cardiovascular Disorders

  • Michael PoteserEmail author
  • Klaus Groschner
  • Ichiro Wakabayashi
Chapter
  • 642 Downloads

Abstract

Molecular etiology of cardiovascular diseases is based on genetic predisposition and environmental factors. While in monogenic forms with Mendelian traits, gene defects are the dominant origin of the disease, the combination and complex interdependence of environmental and genetic factors determine an individual’s risk for common forms of cardiovascular disorders. The molecular pathophysiology of Mendelian traits has been well understood, and a wide range of molecular dysfunctions in key proteins have been identified by examining the pathology of rare genetic defects. Pathomechanisms triggered by environmental factors, on the molecular level, are considered to involve crucial posttranslational modification of signaling molecules with a significant dependence on a genetic susceptibility that is determined by common gene variation. Here, we provide a brief introduction to this concept, focusing on selected paradigms of disease-relevant cellular mechanisms such as modification of proteins by reactive oxygen species, phosphorylation, and glycation. Available information bridging molecular knowledge with epidemiological concepts is highlighted.

Keywords

Genetic predisposition Signaling molecules Oxidative stress Protein ­phosphorylation Protein glycation 

References

  1. Alesutan I, Munoz C, Sopjani M, Dermaku-Sopjani M, Michael D, Fraser S, Kemp BE, Seebohm G, Foller M, Lang F (2011) Inhibition of Kir2.1 (KCNJ2) by the AMP-activated protein kinase. Biochem Biophys Res Commun 408:505–510PubMedGoogle Scholar
  2. Amberg GC, Earley S, Glapa SA (2010) Local regulation of arterial L-type calcium channels by reactive oxygen species. Circ Res 107:1002–1010PubMedGoogle Scholar
  3. An D, Pulinilkunnil T, Qi D, Ghosh S, Abrahani A, Rodrigues B (2005) The metabolic “switch” AMPK regulates cardiac heparin-releasable lipoprotein lipase. Am J Physiol Endocrinol Metab 288:E246–E253PubMedGoogle Scholar
  4. Bao W, Hu E, Tao L, Boyce R, Mirabile R, Thudium DT, Ma XL, Willette RN, Yue TL (2004) Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovasc Res 61:548–558PubMedGoogle Scholar
  5. Beauloye C, Bertrand L, Horman S, Hue L (2011) AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc Res 90:224–233PubMedGoogle Scholar
  6. Bentley JP, Asselbergs FW, Coffey CS, Hebert PR, Moore JH, Hillege HL, van Gilst WH (2010) Cardiovascular risk associated with interactions among polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems. PLoS One 5:e12757PubMedGoogle Scholar
  7. Bidasee KR, Nallani K, Yu Y, Cocklin RR, Zhang Y, Wang M, Dincer UD, Besch HR Jr (2003) Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/calcium-release channels. Diabetes 52:1825–1836PubMedGoogle Scholar
  8. Bidasee KR, Zhang Y, Shao CH, Wang M, Patel KP, Dincer UD, Besch HR Jr (2004) Diabetes increases formation of advanced glycation end products on sarco(endo)plasmic reticulum Ca2+−ATPase. Diabetes 53:463–473PubMedGoogle Scholar
  9. Bivalacqua TJ, Champion HC, Usta MF, Cellek S, Chitaley K, Webb RC, Lewis RL, Mills TM, Hellstrom WJ, Kadowitz PJ (2004) RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA 101:9121–9126PubMedGoogle Scholar
  10. Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ, Fuller SJ, Ben-Levy R, Ashworth A, Marshall CJ, Sugden PH (1996) Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ Res 79:162–173PubMedGoogle Scholar
  11. Bondy B (2007) Common genetic factors for depression and cardiovascular disease. Dialogues Clin Neurosci 9:19–28PubMedGoogle Scholar
  12. Burkle A, Diefenbach J, Brabeck C, Beneke S (2005) Ageing and PARP. Pharmacol Res 52:93–99PubMedGoogle Scholar
  13. Buse MG (2006) Hexosamines, insulin resistance, and the complications of diabetes: current status. Am J Physiol Endocrinol Metab 290:E1–E8PubMedGoogle Scholar
  14. Chang J, Xie M, Shah VR, Schneider MD, Entman ML, Wei L, Schwartz RJ (2006) Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis. Proc Natl Acad Sci USA 103:14495–14500PubMedGoogle Scholar
  15. Chen JX, Stinnett A (2008) Disruption of Ang-1/Tie-2 signaling contributes to the impaired myocardial vascular maturation and angiogenesis in type II diabetic mice. Arterioscler Thromb Vasc Biol 28:1606–1613PubMedGoogle Scholar
  16. Chen AS, Taguchi T, Sugiura M, Wakasugi Y, Kamei A, Wang MW, Miwa I (2004) Pyridoxal-aminoguanidine adduct is more effective than aminoguanidine in preventing neuropathy and cataract in diabetic rats. Horm Metab Res 36:183–187PubMedGoogle Scholar
  17. Chen AF, Chen DD, Daiber A, Faraci FM, Li H, Rembold CM, Laher I (2012) Free radical biology of the cardiovascular system. Clin Sci 123:73–91PubMedGoogle Scholar
  18. Cheng X, Hart GW (2001) Alternative O-glycosylation/O-phosphorylation of serine-16 in murine estrogen receptor beta: post-translational regulation of turnover and transactivation activity. J Biol Chem 276:10570–10575PubMedGoogle Scholar
  19. Cheung WD, Hart GW (2008) AMP-activated protein kinase and p38 MAPK activate O-GlcNAcylation of neuronal proteins during glucose deprivation. J Biol Chem 283:13009–13020PubMedGoogle Scholar
  20. Choukroun G, Hajjar R, Kyriakis JM, Bonventre JV, Rosenzweig A, Force T (1998) Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy. J Clin Invest 102:1311–1320PubMedGoogle Scholar
  21. Cioffi DL (2011) Redox regulation of endothelial canonical transient receptor potential channels. Antioxid Redox Signal 15:1567–1582PubMedGoogle Scholar
  22. Clerk A, Fuller SJ, Michael A, Sugden PH (1998) Stimulation of “stress-regulated” mitogen-­activated protein kinases (stress-activated protein kinases/c-Jun N-terminal kinases and p38-mitogen-activated protein kinases) in perfused rat hearts by oxidative and other stresses. J Biol Chem 273:7228–7234PubMedGoogle Scholar
  23. Colombo SL, Moncada S (2009) AMPKalpha1 regulates the antioxidant status of vascular endothelial cells. Biochem J 421:163–169PubMedGoogle Scholar
  24. Conti A, Scala S, D’Agostino P, Alimenti E, Morelli D, Andria B, Tammaro A, Attanasio C, Della Ragione F, Scuderi V, Fabbrini F, D’Esposito M, Di Florio E, Nitsch L, Calise F, Faiella A (2007) Wide gene expression profiling of ischemia-reperfusion injury in human liver transplantation. Liver Transpl 13:99–113PubMedGoogle Scholar
  25. Csiszar A, Pacher P, Kaley G, Ungvari Z (2005) Role of oxidative and nitrosative stress, longevity genes and poly(ADP-ribose) polymerase in cardiovascular dysfunction associated with aging. Curr Vasc Pharmacol 3:285–291PubMedGoogle Scholar
  26. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM (1990) Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 87:5134–5138PubMedGoogle Scholar
  27. Donoso P, Sanchez G, Bull R, Hidalgo C (2011) Modulation of cardiac ryanodine receptor activity by ROS and RNS. Front Biosci 16:553–567Google Scholar
  28. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M (2000) Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 97:12222–12226PubMedGoogle Scholar
  29. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M (2001) Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108:1341–1348PubMedGoogle Scholar
  30. Du X, Edelstein D, Obici S, Higham N, Zou MH, Brownlee M (2006) Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest 116:1071–1080PubMedGoogle Scholar
  31. Eichers ER, Lewis RA, Katsanis N, Lupski JR (2004) Triallelic inheritance: a bridge between Mendelian and multifactorial traits. Ann Med 36:262–272PubMedGoogle Scholar
  32. El Jamali A, Valente AJ, Lechleiter JD, Gamez MJ, Pearson DW, Nauseef WM, Clark RA (2008) Novel redox-dependent regulation of NOX5 by the tyrosine kinase c-Abl. Free Radic Biol Med 44:868–881PubMedGoogle Scholar
  33. Federici M, Menghini R, Mauriello A, Hribal ML, Ferrelli F, Lauro D, Sbraccia P, Spagnoli LG, Sesti G, Lauro R (2002) Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 106:466–472PubMedGoogle Scholar
  34. Feng Y, Schreiner GF, Chakravarty S, Liu DY, Joly AH (2001) Inhibition of the mitogen activated protein kinase, p38 alpha, prevents proinflammatory cytokine induction by human adherent mononuclear leukocytes in response to lipid loading. Atherosclerosis 158:331–338PubMedGoogle Scholar
  35. Fernandez-Patron C, Radomski MW, Davidge ST (1999) Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85:906–911PubMedGoogle Scholar
  36. Fineschi V, Silver MD, Karch SB, Parolini M, Turillazzi E, Pomara C, Baroldi G (2005) Myocardial disarray: an architectural disorganization linked with adrenergic stress? Int J Cardiol 99:277–282PubMedGoogle Scholar
  37. Florea SM, Blatter LA (2008) The effect of oxidative stress on Ca2+ release and capacitative Ca2+ entry in vascular endothelial cells. Cell Calcium 43:405–415PubMedGoogle Scholar
  38. Francis-Sedlak ME, Moya ML, Huang JJ, Lucas SA, Chandrasekharan N, Larson JC, Cheng MH, Brey EM (2010) Collagen glycation alters neovascularization in vitro and in vivo. Microvasc Res 80:3–9PubMedGoogle Scholar
  39. Fukata Y, Oshiro N, Kinoshita N, Kawano Y, Matsuoka Y, Bennett V, Matsuura Y, Kaibuchi K (1999) Phosphorylation of adducin by Rho-kinase plays a crucial role in cell motility. J Cell Biol 145:347–361PubMedGoogle Scholar
  40. Fulop N, Zhang Z, Marchase RB, Chatham JC (2007) Glucosamine cardioprotection in perfused rat hearts associated with increased O-linked N-acetylglucosamine protein modification and altered p38 activation. Am J Physiol Heart Circ Physiol 292:H2227–H2236PubMedGoogle Scholar
  41. Galis ZS, Khatri JJ (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90:251–262PubMedGoogle Scholar
  42. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements JM, Crimmin M, Davidson AH, Drummond AH, Galloway WA, Gilbert R et al (1995) Matrix metalloproteinases and processing of pro-TNF-alpha. J Leukoc Biol 57:774–777PubMedGoogle Scholar
  43. Gehmlich K, Geier C, Osterziel KJ, Van der Ven PF, Furst DO (2004) Decreased interactions of mutant muscle LIM protein (MLP) with N-RAP and alpha-actinin and their implication for hypertrophic cardiomyopathy. Cell Tissue Res 317:129–136PubMedGoogle Scholar
  44. Gerrits EG, Lutgers HL, Kleefstra N, Graaff R, Groenier KH, Smit AJ, Gans RO, Bilo HJ (2008) Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 31:517–521PubMedGoogle Scholar
  45. Greaves SC, Roche AH, Neutze JM, Whitlock RM, Veale AM (1987) Inheritance of hypertrophic cardiomyopathy: a cross sectional and M mode echocardiographic study of 50 families. Br Heart J 58:259–266PubMedGoogle Scholar
  46. Hanninen SL, Ronkainen JJ, Leskinen H, Tavi P (2010) Mitochondrial uncoupling downregulates calsequestrin expression and reduces SR Ca2+ stores in cardiomyocytes. Cardiovasc Res 88:75–82PubMedGoogle Scholar
  47. Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ (2007) Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail 9:1146–1155PubMedGoogle Scholar
  48. Hattori T, Shimokawa H, Higashi M, Hiroki J, Mukai Y, Tsutsui H, Kaibuchi K, Takeshita A (2004) Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 109:2234–2239PubMedGoogle Scholar
  49. Heidrich F, Schotola H, Popov AF, Sohns C, Chuenemann J, Friedrich M, Coskun KO, von Lewinski D, Hinz J, Bauer M, Mokashi SA, Sossalla S, Schmitto JD (2010) AMPK – activated protein kinase and its role in energy metabolism of the heart. Curr Cardiol Rev 6:337–342PubMedGoogle Scholar
  50. Hidaka T, Hata T, Soga J, Fujii Y, Idei N, Fujimura N, Kihara Y, Noma K, Liao JK, Higashi Y (2010) Increased leukocyte rho kinase (ROCK) activity and endothelial dysfunction in cigarette smokers. Hypertens Res 33:354–359PubMedGoogle Scholar
  51. Hool LC, Di Maria CA, Viola HM, Arthur PG (2005) Role of NAD(P)H oxidase in the regulation of cardiac L-type Ca2+ channel function during acute hypoxia. Cardiovasc Res 67:624–635PubMedGoogle Scholar
  52. Ikematsu N, Dallas ML, Ross FA, Lewis RW, Rafferty JN, David JA, Suman R, Peers C, Hardie DG, Evans AM (2011) Phosphorylation of the voltage-gated potassium channel Kv2.1 by AMP-activated protein kinase regulates membrane excitability. Proc Natl Acad Sci USA 108:18132–18137PubMedGoogle Scholar
  53. Inada H, Togashi H, Nakamura Y, Kaibuchi K, Nagata K, Inagaki M (1999) Balance between activities of Rho kinase and type 1 protein phosphatase modulates turnover of phosphorylation and dynamics of desmin/vimentin filaments. J Biol Chem 274:34932–34939PubMedGoogle Scholar
  54. Inoue N, Okamura T, Kokubo Y, Fujita Y, Sato Y, Nakanishi M, Yanagida K, Kakino A, Iwamoto S, Watanabe M, Ogura S, Otsui K, Matsuda H, Uchida K, Yoshimoto R, Sawamura T (2010) LOX index, a novel predictive biochemical marker for coronary heart disease and stroke. Clin Chem 56:550–558PubMedGoogle Scholar
  55. Iwasaki K, Hayashi K, Fujioka T, Sobue K (2008) Rho/Rho-associated kinase signal regulates myogenic differentiation via myocardin-related transcription factor-A/Smad-dependent transcription of the Id3 gene. J Biol Chem 283:21230–21241PubMedGoogle Scholar
  56. Jiang SY, Xu M, Ma XW, Xiao H, Zhang YY (2010) A distinct AMP-activated protein kinase phosphorylation site characterizes cardiac hypertrophy induced by L-thyroxine and angiotensin II. Clin Exp Pharmacol Physiol 37:919–925PubMedGoogle Scholar
  57. Johnson GL, Nakamura K (2007) The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim Biophys Acta 1773:1341–1348PubMedGoogle Scholar
  58. Judkins CP, Diep H, Broughton BR, Mast AE, Hooker EU, Miller AA, Selemidis S, Dusting GJ, Sobey CG, Drummond GR (2010) Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE−/− mice. Am J Physiol Heart Circ Physiol 298:H24–H32PubMedGoogle Scholar
  59. Kambara T, Ohashi K, Shibata R, Ogura Y, Maruyama S, Enomoto T, Uemura Y, Shimizu Y, Yuasa D, Matsuo K, Miyabe M, Kataoka Y, Murohara T, Ouchi N (2012) CTRP9 protein protects against myocardial injury following ischemia-reperfusion through AMP-activated protein kinase (AMPK)-dependent mechanism. J Biol Chem 287:18965–18973PubMedGoogle Scholar
  60. Kamemura K, Hayes BK, Comer FI, Hart GW (2002) Dynamic interplay between O-glycosylation and O-phosphorylation of nucleocytoplasmic proteins: alternative glycosylation/phosphorylation of THR-58, a known mutational hot spot of c-Myc in lymphomas, is regulated by mitogens. J Biol Chem 277:19229–19235PubMedGoogle Scholar
  61. Kamioka M, Ishibashi T, Ohkawara H, Nagai R, Sugimoto K, Uekita H, Matsui T, Yamagishi S, Ando K, Sakamoto T, Sakamoto N, Takuwa Y, Wada I, Shiomi M, Maruyama Y, Takeishi Y (2011) Involvement of membrane type 1-matrix metalloproteinase (MT1-MMP) in RAGE activation signaling pathways. J Cell Physiol 226:1554–1563PubMedGoogle Scholar
  62. Kandabashi T, Shimokawa H, Miyata K, Kunihiro I, Kawano Y, Fukata Y, Higo T, Egashira K, Takahashi S, Kaibuchi K, Takeshita A (2000) Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. Circulation 101:1319–1323PubMedGoogle Scholar
  63. Kandabashi T, Shimokawa H, Mukai Y, Matoba T, Kunihiro I, Morikawa K, Ito M, Takahashi S, Kaibuchi K, Takeshita A (2002) Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries. Arterioscler Thromb Vasc Biol 22:243–248PubMedGoogle Scholar
  64. Kawai T, Kamide K, Ito N, Onishi M, Oguro R, Takeya Y, Tatara Y, Maekawa Y, Katsuya T, Ohishi M, Rakugi H (2013) -374 T/A polymorphism in RAGE gene is associated with onset of diabetes mellitus, atherosclerosis, and renal dysfunction in patients with hypertension. Clin Exp Hypertens 35(3):236–241PubMedGoogle Scholar
  65. Kehat I, Molkentin JD (2010) Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 122:2727–2735PubMedGoogle Scholar
  66. Kelly WG, Dahmus ME, Hart GW (1993) RNA polymerase II is a glycoprotein. Modification of the COOH-terminal domain by O-GlcNAc. J Biol Chem 268:10416–10424PubMedGoogle Scholar
  67. Kikuchi Y, Yasuda S, Aizawa K, Tsuburaya R, Ito Y, Takeda M, Nakayama M, Ito K, Takahashi J, Shimokawa H (2011) Enhanced Rho-kinase activity in circulating neutrophils of patients with vasospastic angina: a possible biomarker for diagnosis and disease activity assessment. J Am Coll Cardiol 58:1231–1237PubMedGoogle Scholar
  68. Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF (1999) Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 22:1543–1548PubMedGoogle Scholar
  69. Koyama Y, Takeishi Y, Arimoto T, Niizeki T, Shishido T, Takahashi H, Nozaki N, Hirono O, Tsunoda Y, Nitobe J, Watanabe T, Kubota I (2007) High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail 13:199–206PubMedGoogle Scholar
  70. Kuwahara K, Nishikimi T, Nakao K (2012) Transcriptional regulation of the fetal cardiac gene program. J Pharmacol Sci 119:198–203PubMedGoogle Scholar
  71. Laczy B, Hill BG, Wang K, Paterson AJ, White CR, Xing D, Chen YF, Darley-Usmar V, Oparil S, Chatham JC (2009) Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system. Am J Physiol Heart Circ Physiol 296:H13–H28PubMedGoogle Scholar
  72. Lee M, Spokes KC, Aird WC, Abid MR (2010) Intracellular Ca2+ can compensate for the lack of NADPH oxidase-derived ROS in endothelial cells. FEBS Lett 584:3131–3136PubMedGoogle Scholar
  73. Lee YC, Lai CQ, Ordovas JM, Parnell LD (2011) A database of gene-environment interactions pertaining to blood lipid traits, cardiovascular disease and type 2 diabetes. J Data Mining Genomics Proteomics 2(1) pii:106Google Scholar
  74. Li F, Xia W, Yuan S, Sun R (2009) Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease. Pediatr Cardiol 30:363–366PubMedGoogle Scholar
  75. Liang Q, Molkentin JD (2003) Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. J Mol Cell Cardiol 35:1385–1394PubMedGoogle Scholar
  76. Lieb W, Mayer B, Konig IR, Borwitzky I, Gotz A, Kain S, Hengstenberg C, Linsel-Nitschke P, Fischer M, Doring A, Wichmann HE, Meitinger T, Kreutz R, Ziegler A, Schunkert H, Erdmann J (2008) Lack of association between the MEF2A gene and myocardial infarction. Circulation 117:185–191PubMedGoogle Scholar
  77. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM (1992) A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355:262–265PubMedGoogle Scholar
  78. Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, Roberts R, Marian AJ (2001) Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103:789–791PubMedGoogle Scholar
  79. Lim HS, Patel JV, Lip GY (2006) Reactive oxygen species production by circulating monocytes: insights from pathophysiology to clinical hypertension. J Hum Hypertens 20:307–309PubMedGoogle Scholar
  80. Lima VV, Giachini FR, Carneiro FS, Carneiro ZN, Saleh MA, Pollock DM, Fortes ZB, Carvalho MH, Ergul A, Webb RC, Tostes RC (2010) O-GlcNAcylation contributes to augmented vascular reactivity induced by endothelin 1. Hypertension 55:180–188PubMedGoogle Scholar
  81. Lima VV, Giachini FR, Carneiro FS, Carvalho MH, Fortes ZB, Webb RC, Tostes RC (2011) O-GlcNAcylation contributes to the vascular effects of ET-1 via activation of the RhoA/Rho-kinase pathway. Cardiovasc Res 89:614–622PubMedGoogle Scholar
  82. Liu AJ, Ling F, Wang D, Wang Q, Lu XD, Liu YL (2011) Fasudil inhibits platelet-derived growth factor-induced human pulmonary artery smooth muscle cell proliferation by up-regulation of p27kip(1) via the ERK signal pathway. Chin Med J (Engl) 124:3098–3104Google Scholar
  83. Mallat Z, Gojova A, Sauzeau V, Brun V, Silvestre JS, Esposito B, Merval R, Groux H, Loirand G, Tedgui A (2003) Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ Res 93:884–888PubMedGoogle Scholar
  84. Mani A, Radhakrishnan J, Wang H, Mani MA, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D, Lifton RP (2007) LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 315:1278–1282PubMedGoogle Scholar
  85. Marian AJ (2000) Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 355:58–60PubMedGoogle Scholar
  86. Marian AJ, Wu Y, Lim DS, McCluggage M, Youker K, Yu QT, Brugada R, DeMayo F, Quinones M, Roberts R (1999) A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Invest 104:1683–1692PubMedGoogle Scholar
  87. Marsh SA, Dell’Italia LJ, Chatham JC (2011) Activation of the hexosamine biosynthesis pathway and protein O-GlcNAcylation modulate hypertrophic and cell signaling pathways in cardiomyocytes from diabetic mice. Amino Acids 40:819–828PubMedGoogle Scholar
  88. Marshall S, Bacote V, Traxinger RR (1991) Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem 266:4706–4712PubMedGoogle Scholar
  89. McEver RP (1992) Leukocyte-endothelial cell interactions. Curr Opin Cell Biol 4:840–849PubMedGoogle Scholar
  90. McLaren JE, Michael DR, Ashlin TG, Ramji DP (2011) Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res 50:331–347PubMedGoogle Scholar
  91. Metzler B, Hu Y, Dietrich H, Xu Q (2000) Increased expression and activation of stress-activated protein kinases/c-Jun NH(2)-terminal protein kinases in atherosclerotic lesions coincide with p53. Am J Pathol 156:1875–1886PubMedGoogle Scholar
  92. Miyamoto SD, Stauffer BL, Nakano S, Sobus R, Nunley K, Nelson P, Sucharov CC (2012) Beta-adrenergic adaptation in paediatric idiopathic dilated cardiomyopathy. Eur Heart J [Epub ahead of print].  doi:10.1093/eurheartj/ehs229
  93. Morooka H, Bonventre JV, Pombo CM, Kyriakis JM, Force T (1995) Ischemia and reperfusion enhance ATF-2 and c-Jun binding to cAMP response elements and to an AP-1 binding site from the c-jun promoter. J Biol Chem 270:30084–30092PubMedGoogle Scholar
  94. Mueller BK, Mack H, Teusch N (2005) Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 4:387–398PubMedGoogle Scholar
  95. Muller M, Mazur AJ, Behrmann E, Diensthuber RP, Radke MB, Qu Z, Littwitz C, Raunser S, Schoenenberger CA, Manstein DJ, Mannherz HG (2012) Functional characterization of the human alpha-cardiac actin mutations Y166C and M305L involved in hypertrophic cardiomyopathy. Cell Mol Life Sci 69:3457–3479PubMedGoogle Scholar
  96. Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K, Horiuchi S (1997) The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 40:764–769PubMedGoogle Scholar
  97. Murphy M, Godson C, Cannon S, Kato S, Mackenzie HS, Martin F, Brady HR (1999) Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 274:5830–5834PubMedGoogle Scholar
  98. Nathan DM (1996) The pathophysiology of diabetic complications: how much does the glucose hypothesis explain? Ann Intern Med 124:86–89PubMedGoogle Scholar
  99. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:14998–15004PubMedGoogle Scholar
  100. Ngoh GA, Facundo HT, Zafir A, Jones SP (2010) O-GlcNAc signaling in the cardiovascular system. Circ Res 107:171–185PubMedGoogle Scholar
  101. Noma K, Kihara Y, Higashi Y (2012) Striking crosstalk of ROCK signaling with endothelial function. J Cardiol 60:1–6PubMedGoogle Scholar
  102. Oberst L, Zhao G, Park JT, Brugada R, Michael LH, Entman ML, Roberts R, Marian AJ (1998) Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. J Clin Invest 102:1498–1505PubMedGoogle Scholar
  103. Ohtsu H, Mifune M, Frank GD, Saito S, Inagami T, Kim-Mitsuyama S, Takuwa Y, Sasaki T, Rothstein JD, Suzuki H, Nakashima H, Woolfolk EA, Motley ED, Eguchi S (2005) Signal-crosstalk between Rho/ROCK and c-Jun NH2-terminal kinase mediates migration of vascular smooth muscle cells stimulated by angiotensin II. Arterioscler Thromb Vasc Biol 25:1831–1836PubMedGoogle Scholar
  104. Omar MA, Verma S, Clanachan AS (2012) Adenosine-mediated inhibition of 5′-AMP-activated protein kinase and p38 mitogen-activated protein kinase during reperfusion enhances recovery of left ventricular mechanical function. J Mol Cell Cardiol 52:1308–1318PubMedGoogle Scholar
  105. Ordovas JM (2007) Genetic links between diabetes mellitus and coronary atherosclerosis. Curr Atheroscler Rep 9:204–210PubMedGoogle Scholar
  106. Ostman-Smith I, Wettrell G (2000) Pathophysiology of hypertrophic cardiomyopathy. Lancet 355:928PubMedGoogle Scholar
  107. Oudit GY, Kassiri Z, Patel MP, Chappell M, Butany J, Backx PH, Tsushima RG, Scholey JW, Khokha R, Penninger JM (2007) Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res 75:29–39PubMedGoogle Scholar
  108. Pace L, Betocchi S, Losi MA, Della Morte AM, Ciampi Q, Nugnez R, Chiariello M, Salvatore M (2004) Sympathetic nervous function in patients with hypertrophic cardiomyopathy assessed by [123I]-MIBG: relationship with left ventricular perfusion and function. Q J Nucl Med Mol Imaging 48:20–25PubMedGoogle Scholar
  109. Paiva MA, Rutter-Locher Z, Goncalves LM, Providencia LA, Davidson SM, Yellon DM, Mocanu MM (2011) Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury. Am J Physiol Heart Circ Physiol 300:H2123–H2134PubMedGoogle Scholar
  110. Pandey D, Gratton JP, Rafikov R, Black SM, Fulton DJ (2011) Calcium/calmodulin-dependent kinase II mediates the phosphorylation and activation of NADPH oxidase 5. Mol Pharmacol 80:407–415PubMedGoogle Scholar
  111. Patel R, Lim DS, Reddy D, Nagueh SF, Lutucuta S, Sole MJ, Zoghbi WA, Quinones MA, Roberts R, Marian AJ (2000) Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy. J Mol Cell Cardiol 32:2369–2377PubMedGoogle Scholar
  112. Peng TI, Jou MJ (2010) Oxidative stress caused by mitochondrial calcium overload. Ann N Y Acad Sci 1201:183–188PubMedGoogle Scholar
  113. Pombo CM, Bonventre JV, Avruch J, Woodgett JR, Kyriakis JM, Force T (1994) The stress-activated protein kinases are major c-Jun amino-terminal kinases activated by ischemia and reperfusion. J Biol Chem 269:26546–26551PubMedGoogle Scholar
  114. Porter K, Medford HM, McIntosh CM, Marsh SA (2012) Cardioprotection requires flipping the ‘posttranslational modification’ switch. Life Sci 90:89–98PubMedGoogle Scholar
  115. Poteser M, Graziani A, Rosker C, Eder P, Derler I, Kahr H, Zhu MX, Romanin C, Groschner K (2006) TRPC3 and TRPC4 associate to form a redox-sensitive cation channel. Evidence for expression of native TRPC3-TRPC4 heteromeric channels in endothelial cells. J Biol Chem 281:13588–13595PubMedGoogle Scholar
  116. Qu MJ, Liu B, Qi YX, Jiang ZL (2008) Role of Rac and Rho-GDI alpha in the frequency-dependent expression of h1-calponin in vascular smooth muscle cells under cyclic mechanical strain. Ann Biomed Eng 36:1481–1488PubMedGoogle Scholar
  117. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, Lusis AJ (1990) Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 344:254–257PubMedGoogle Scholar
  118. Raman P, Krukovets I, Marinic TE, Bornstein P, Stenina OI (2007) Glycosylation mediates up-regulation of a potent antiangiogenic and proatherogenic protein, thrombospondin-1, by glucose in vascular smooth muscle cells. J Biol Chem 282:5704–5714PubMedGoogle Scholar
  119. Raposeiras-Roubin S, Rodino-Janeiro BK, Grigorian-Shamagian L, Moure-Gonzalez M, Seoane-Blanco A, Varela-Roman A, Alvarez E, Gonzalez-Juanatey JR (2010) Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: New Roles for Soluble RAGE. Eur J Heart Fail 12:1092–1100PubMedGoogle Scholar
  120. Rayment I, Holden HM, Sellers JR, Fananapazir L, Epstein ND (1995) Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 92:3864–3868PubMedGoogle Scholar
  121. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, Burban M, Gueffet JP, Millaire A, Desnos M, Schwartz K, Hainque B, Komajda M (2003) Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107:2227–2232PubMedGoogle Scholar
  122. Romanoski CE, Lee S, Kim MJ, Ingram-Drake L, Plaisier CL, Yordanova R, Tilford C, Guan B, He A, Gargalovic PS, Kirchgessner TG, Berliner JA, Lusis AJ (2010) Systems genetics analysis of gene-by-environment interactions in human cells. Am J Hum Genet 86:399–410PubMedGoogle Scholar
  123. Rysev NA, Karpicheva OE, Redwood CS, Borovikov YS (2012) The effect of the Asp175Asn and Glu180Gly TPM1 mutations on actin-myosin interaction during the ATPase cycle. Biochim Biophys Acta 1824:366–373PubMedGoogle Scholar
  124. Saely CH, Muendlein A, Vonbank A, Sonderegger G, Aczel S, Rein P, Risch L, Drexel H (2008) Type 2 diabetes significantly modulates the cardiovascular risk conferred by the PAI-1–675 4G/5G polymorphism in angiographied coronary patients. Clin Chim Acta 396:18–22PubMedGoogle Scholar
  125. Santos KG, Crispim D, Canani LH, Ferrugem PT, Gross JL, Roisenberg I (2012) Relationship of endothelial nitric oxide synthase (eNOS) gene polymorphisms with diabetic retinopathy in Caucasians with type 2 diabetes. Ophthalmic Genet 33:23–27PubMedGoogle Scholar
  126. Schwartz D, Andalibi A, Chaverri-Almada L, Berliner JA, Kirchgessner T, Fang ZT, Tekamp-Olson P, Lusis AJ, Gallegos C, Fogelman AM et al (1994) Role of the GRO family of chemokines in monocyte adhesion to MM-LDL-stimulated endothelium. J Clin Invest 94:1968–1973PubMedGoogle Scholar
  127. Seko Y, Takahashi N, Tobe K, Kadowaki T, Yazaki Y (1997) Hypoxia and hypoxia/reoxygenation activate p65PAK, p38 mitogen-activated protein kinase (MAPK), and stress-activated protein kinase (SAPK) in cultured rat cardiac myocytes. Biochem Biophys Res Commun 239:840–844PubMedGoogle Scholar
  128. Shao D, Oka S, Brady CD, Haendeler J, Eaton P, Sadoshima J (2012) Redox modification of cell signaling in the cardiovascular system. J Mol Cell Cardiol 52:550–558PubMedGoogle Scholar
  129. Simm A, Wagner J, Gursinsky T, Nass N, Friedrich I, Schinzel R, Czeslik E, Silber RE, Scheubel RJ (2007) Advanced glycation endproducts: a biomarker for age as an outcome predictor after cardiac surgery? Exp Gerontol 42:668–675PubMedGoogle Scholar
  130. Singh R, Barden A, Mori T, Beilin L (2001) Advanced glycation end-products: a review. Diabetologia 44:129–146PubMedGoogle Scholar
  131. Soga J, Noma K, Hata T, Hidaka T, Fujii Y, Idei N, Fujimura N, Mikami S, Maruhashi T, Kihara Y, Chayama K, Kato H, Liao JK, Higashi Y (2011) Rho-associated kinase activity, endothelial function, and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 31:2353–2359PubMedGoogle Scholar
  132. Spiro RG (2002) Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 12:43R–56RPubMedGoogle Scholar
  133. Stenina OI, Byzova TV, Adams JC, McCarthy JJ, Topol EJ, Plow EF (2004) Coronary artery disease and the thrombospondin single nucleotide polymorphisms. Int J Biochem Cell Biol 36:1013–1030PubMedGoogle Scholar
  134. Sun L, Yau HY, Lau OC, Huang Y, Yao X (2011) Effect of hydrogen peroxide and superoxide anions on cytosolic Ca2+: comparison of endothelial cells from large-sized and small-sized arteries. PLoS One 6:e25432PubMedGoogle Scholar
  135. Tsounapi P, Saito M, Kitatani K, Dimitriadis F, Ohmasa F, Shimizu S, Kinoshita Y, Takenaka A, Satoh K (2012) Fasudil improves the endothelial dysfunction in the aorta of spontaneously hypertensive rats. Eur J Pharmacol 691:182–189PubMedGoogle Scholar
  136. Uchida K, Suehiro A, Nakanishi M, Sawamura T, Wakabayashi I (2011) Associations of atherosclerotic risk factors with oxidized low-density lipoprotein evaluated by LOX-1 ligand activity in healthy men. Clin Chim Acta 412:1643–1647PubMedGoogle Scholar
  137. Vahebi S, Kobayashi T, Warren CM, de Tombe PP, Solaro RJ (2005) Functional effects of rho-kinase-dependent phosphorylation of specific sites on cardiac troponin. Circ Res 96:740–747PubMedGoogle Scholar
  138. Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KA, de Geest H, Verstraete M, Collen D, Sobel BE (1984) Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med 310:609–613PubMedGoogle Scholar
  139. Van Driest SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ, Ackerman MJ (2004) Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol 44:1903–1910PubMedGoogle Scholar
  140. Vasile VC, Ommen SR, Edwards WD, Ackerman MJ (2006) A missense mutation in a ubiquitously expressed protein, vinculin, confers susceptibility to hypertrophic cardiomyopathy. Biochem Biophys Res Commun 345:998–1003PubMedGoogle Scholar
  141. Victor VM, Apostolova N, Herance R, Hernandez-Mijares A, Rocha M (2009) Oxidative stress and mitochondrial dysfunction in atherosclerosis: mitochondria-targeted antioxidants as potential therapy. Curr Med Chem 16:4654–4667PubMedGoogle Scholar
  142. Vikstrom KL, Factor SM, Leinwand LA (1995) A murine model for hypertrophic cardiomyopathy. Z Kardiol 84(Suppl 4):49–54PubMedGoogle Scholar
  143. Vora DK, Fang ZT, Liva SM, Tyner TR, Parhami F, Watson AD, Drake TA, Territo MC, Berliner JA (1997) Induction of P-selectin by oxidized lipoproteins. Separate effects on synthesis and surface expression. Circ Res 80:810–818PubMedGoogle Scholar
  144. Wang YX, Martin-McNulty B, da Cunha V, Vincelette J, Lu X, Feng Q, Halks-Miller M, Mahmoudi M, Schroeder M, Subramanyam B, Tseng JL, Deng GD, Schirm S, Johns A, Kauser K, Dole WP, Light DR (2005) Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. Circulation 111:2219–2226PubMedGoogle Scholar
  145. Wang Z, Pandey A, Hart GW (2007) Dynamic interplay between O-linked N-acetylglucosaminylation and glycogen synthase kinase-3-dependent phosphorylation. Mol Cell Proteomics 6:1365–1379PubMedGoogle Scholar
  146. Wang H, Li Z, Wang J, Sun K, Cui Q, Song L, Zou Y, Wang X, Liu X, Hui R, Fan Y (2010a) Mutations in NEXN, a Z-disc gene, are associated with hypertrophic cardiomyopathy. Am J Hum Genet 87:687–693PubMedGoogle Scholar
  147. Wang M, Zhang J, Walker SJ, Dworakowski R, Lakatta EG, Shah AM (2010b) Involvement of NADPH oxidase in age-associated cardiac remodeling. J Mol Cell Cardiol 48:765–772PubMedGoogle Scholar
  148. Weissmann N, Sydykov A, Kalwa H, Storch U, Fuchs B, Mederos y Schnitzler M, Brandes RP, Grimminger F, Meissner M, Freichel M, Offermanns S, Veit F, Pak O, Krause KH, Schermuly RT, Brewer AC, Schmidt HH, Seeger W, Shah AM, Gudermann T, Ghofrani HA, Dietrich A (2012) Activation of TRPC6 channels is essential for lung ischaemia-reperfusion induced oedema in mice. Nat Commun 3:649PubMedGoogle Scholar
  149. Weng L, Kavaslar N, Ustaszewska A, Doelle H, Schackwitz W, Hebert S, Cohen JC, McPherson R, Pennacchio LA (2005) Lack of MEF2A mutations in coronary artery disease. J Clin Invest 115:1016–1020PubMedGoogle Scholar
  150. Witztum JL, Steinberg D (1991) Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88:1785–1792PubMedGoogle Scholar
  151. Yang WH, Kim JE, Nam HW, Ju JW, Kim HS, Kim YS, Cho JW (2006) Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat Cell Biol 8:1074–1083PubMedGoogle Scholar
  152. Yao D, Taguchi T, Matsumura T, Pestell R, Edelstein D, Giardino I, Suske G, Rabbani N, Thornalley PJ, Sarthy VP, Hammes HP, Brownlee M (2007) High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem 282:31038–31045PubMedGoogle Scholar
  153. Yevdokimova N, Wahab NA, Mason RM (2001) Thrombospondin-1 is the key activator of TGF-beta1 in human mesangial cells exposed to high glucose. J Am Soc Nephrol 12:703–712PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2013

Authors and Affiliations

  • Michael Poteser
    • 1
    Email author
  • Klaus Groschner
    • 1
  • Ichiro Wakabayashi
    • 2
  1. 1.Center for Physiological Medicine, Institute of BiophysicsMedical University of GrazGrazAustria
  2. 2.Department of Environmental and Preventive MedicineHyogo College of MedicineNishinomiyaJapan

Personalised recommendations